

# CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies

<https://marketpublishers.com/r/C933974CFCEEN.html>

Date: October 2016

Pages: 20

Price: US\$ 225.00 (Single User License)

ID: C933974CFCEEN

## Abstracts

CD123-Targeted Immunotherapeutics in:

September 2016 R&D and Business Tracker for Bispecific Antibodies

This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.

Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics, the profile of Swiss pharmaceutical company Neovii Pharmaceuticals and the bispecific antibody profile of AMV-564 from Amphivena Therapeutics.

The September 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;

T-Cell redirecting bispecific cancer antibodies

NK cell redirecting bispecific cancer antibodies

Bispecific immuno-oncology antibodies

Bispecific tumor antigens targeted cancer antibodies

Bispecific antibodies for inflammatory & autoimmune diseases

Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

Pipeline changes

Regulatory news

Technology validations

Manufacturing news

Business Tracker for:

Company updates

Collaboration

Licensing

Merger & acquisitions

Financing

Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Antibody Profile: AMV-564

Featured Company Profile: Neovii Pharmaceuticals

## Featured Target or Technology Pipeline: CD123-Targeted Immunotherapeutics

### CD123-Targeted Immunotherapeutics:

Antibody-Drug Conjugates

Immunotoxins

Fc-Engineered Antibodies

T-cell Redirecting Bispecific Antibodies

CAR T-Cells

Information about the CD123-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

### **Methodology:**

Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing's proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

### **Customized Update Service:**

The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.

## I would like to order

Product name: CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies

Product link: <https://marketpublishers.com/r/C933974CFCEEN.html>

Price: US\$ 225.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C933974CFCEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

